PROTAC Library

Loading...
E3 Ligase
Target
Molecular Weight
to
Your selection
  • Your selection
Structure Catalog Product Name CAS E3 Ligase Target Inquiry
(E)-N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide BPL-202513 (E)-N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 922.22

Molecular Formula: C43H43Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
(E)-N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide BPL-202514 (E)-N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 936.25

Molecular Formula: C44H45Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
(E)-N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide BPL-202515 (E)-N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 950.28

Molecular Formula: C45H47Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
(E)-N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide BPL-202516 (E)-N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide

CRBN

KRAS G12C

 Inquiry

Molecular Weight: 978.33

Molecular Formula: C47H51Cl3N8O9

Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
N-(17-(4-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-2,3-dichlorophenyl)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide BPL-202517 N-(17-(4-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-2,3-dichlorophenyl)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide

CRBN

SHP2

 Inquiry

Molecular Weight: 929.86

Molecular Formula: C43H54Cl2N8O11

Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
N-(17-(3-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-4,5-dichlorophenyl)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide BPL-202518 N-(17-(3-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-4,5-dichlorophenyl)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide

CRBN

SHP2

 Inquiry

Molecular Weight: 929.86

Molecular Formula: C43H54Cl2N8O11

Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
N-(17-(4-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide BPL-202519 N-(17-(4-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide

CRBN

SHP2

 Inquiry

Molecular Weight: 945.86

Molecular Formula: C43H54Cl2N8O12

Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
N-(17-(3-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-4,5-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide BPL-202520 N-(17-(3-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-4,5-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide

CRBN

SHP2

 Inquiry

Molecular Weight: 945.86

Molecular Formula: C43H54Cl2N8O12

Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
N-(2-(2-(2-(2-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide BPL-202521 N-(2-(2-(2-(2-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide

CRBN

SHP2
SHP2 F285S

 Inquiry

Molecular Weight: 942.85

Molecular Formula: C44H53Cl2N7O12

Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
N-(17-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide BPL-202522 N-(17-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide

CRBN

SHP2
SHP2 F285S

 Inquiry

Molecular Weight: 1030.96

Molecular Formula: C48H61Cl2N7O14

Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
N-(23-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15,18,21-heptaoxatricosyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide BPL-202523 N-(23-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15,18,21-heptaoxatricosyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide

CRBN

SHP2
SHP2 F285S

 Inquiry

Molecular Weight: 1119.06

Molecular Formula: C52H69Cl2N7O16

Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
MA055 BPL-202524 MA055

VHL

Wee1

 Inquiry

Molecular Weight: 985.23

Molecular Formula: C52H64N12O6S

Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
(2S,4R)-1-((S)-2-(4-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide BPL-202525 (2S,4R)-1-((S)-2-(4-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

VHL

Wee1

 Inquiry

Molecular Weight: 1070.33

Molecular Formula: C56H71N13O7S

Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
(2S,4R)-1-((S)-2-(6-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide BPL-202526 (2S,4R)-1-((S)-2-(6-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

VHL

Wee1

 Inquiry

Molecular Weight: 1098.39

Molecular Formula: C58H75N13O7S

Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
(2S,4R)-1-((S)-2-(8-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide BPL-202527 (2S,4R)-1-((S)-2-(8-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

VHL

Wee1

 Inquiry

Molecular Weight: 1126.44

Molecular Formula: C60H79N13O7S

Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
(2S,4R)-1-((S)-2-(11-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide BPL-202528 (2S,4R)-1-((S)-2-(11-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

VHL

Wee1

 Inquiry

Molecular Weight: 1168.52

Molecular Formula: C63H85N13O7S

Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
(2S,4R)-1-((S)-19-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-2-(tert-butyl)-4,16-dioxo-6,9,12-trioxa-3,15-diazanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide BPL-202529 (2S,4R)-1-((S)-19-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-2-(tert-butyl)-4,16-dioxo-6,9,12-trioxa-3,15-diazanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

VHL

Wee1

 Inquiry

Molecular Weight: 1174.44

Molecular Formula: C60H79N13O10S

Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
(2S,4R)-1-((S)-23-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-2-(tert-butyl)-4,20-dioxo-7,10,13,16-tetraoxa-3,19-diazatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide BPL-202530 (2S,4R)-1-((S)-23-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-2-(tert-butyl)-4,20-dioxo-7,10,13,16-tetraoxa-3,19-diazatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

VHL

Wee1

 Inquiry

Molecular Weight: 1232.52

Molecular Formula: C63H85N13O11S

Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)butanamide BPL-202531 4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)butanamide

CRBN

Wee1

 Inquiry

Molecular Weight: 870.97

Molecular Formula: C45H50N12O7

Description: It is a PROTAC using AZD1775 linked to the CRBN ligand pomalidomide. It induces the selective degradation of Wee1.
4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)butanamide BPL-202532 4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)butanamide

CRBN

Wee1

 Inquiry

Molecular Weight: 927.08

Molecular Formula: C49H58N12O7

Description: It is a PROTAC using AZD1775 linked to the CRBN ligand pomalidomide. It induces the selective degradation of Wee1.

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Copyright © 2024 BOC Sciences. All Rights Reserved.
Inquiry Basket
Loading ......
Delete selectedGo to checkout